CTOs on the Move


 
Apps that work seamlessly together to create integrated, multichannel programs that empower people to take a dramatically more active role in improving health. Beyond members and patients, this is healthcare IT that helps doctors, providers, health plan administrators and medical device manufacturers. Not to mention Medicare Star Ratings.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Revel raised $17M on 11/29/2017

Similar Companies

Homology Medicines

Homology is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study Section of the NIH. Dr. Chatterjee and her team led the first adeno-associated virus (AAV) vector-mediated gene transfer studies into human hematopoietic stem cells and subsequently identified and isolated a series of naturally-occurring AAVs from human CD34+ cells.

Sanford Jackson Medical Center

Sanford Jackson Medical Center is a Jackson, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scorpion Therapeutics

Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer.

Primera Biosystems Inc d/b/a PrimeraDx

Primera Biosystems Inc d/b/a PrimeraDx is a Mansfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beta Bionics

Beta Bionics is proud to be a Massachusetts public benefit corporation.